Anemia of uremia Is associated with reduced in vitro cytoklne secretion:
postulate and to investigate the role RBC may have in the immune system in vivo. The in vitro secretion of interleukin-2 (IL-2), tinterferon (y-IFN), tumor necrosis factor (TNF) and colony stimulating factor (CSF) by human peripheral blood mononuclear cells isolated from patients and controls was used as a measure of immune function, The following protocols were carried out: IL-2 secretion was measured in patients with end-stage renal disease (ESRD) and in controls. RBCs were transfused to patients with ESRD and secretion of cytokines was measured before, and 4 hours, 4, 7 and 14 days afterwards; patients with ESRD received recombinant human erythropoietin (rHuEpo) and secretion of cytokines was measured before treatment and two and four months later. Finally, the effect of phlebotomy and transfusion of the autologous blood on cytokine secretion in healthy subjects was measured. Secretion of IL-2 by patients with ESRD was substantially lower than that of healthy subjects. In each group, IL-2 secretion correlated positively with hemoglobin level, r = 0.73, Pc 0.01 and r = 0.71, Pc 0.01. Following transfusion of RBC, secretion of all cytokines rose at the early stage of the study and stayed elevated throughout the study period. Following treatment with rHuEpo secretion of the four cytokines rose progressively and in parallel to the rise in hemoglobin level as shown by a positive correlation between each of the cytokines and the hemoglobin level. Phlebotomy caused a significant reduction in the secretion of the four measured cytokines. Transfusion of autologous blood led to a significant rise in cytokine secretion above prephlebotomy levels which persisted throughout the study. These results suggest that the anemia of uremia may be associated with a decreased secretion of cytokines in vitro. This could contribute to the impaired immune response observed in patients with ESRD. Furthermore, RBC appear to potentiate secretion of cytokines. The decreased secretion of cytokines may be corrected in part by RBC transfusion or elevation of hemoglobin levels with rHuEpo treatment.
In vitro studies have demonstrated various stimulatory effects of red blood cells (RBC) on T cell reactivity. RBC have been shown to enhance the response to PHA [1] and natural © 1994 by the International Society of Nephrology to potentiate the response of peripheral blood mononuclear cells (PBMC) to pokeweed mitogen [3] , and to facilitate the induction of primary and secondary specific antibody responses in vitro by mononuclear cells [4] . Furthermore, B and T lymphocyte colony formation was significantly enhanced by sheep RBC added to the culture medium [5, 6] . In a recent study, RBC were found to enhance secretion of various cytokines by human PBMC and mouse spleen cells [7] . In contrast, data on the in vivo effects of RBC are limited. Whole blood transfusion (BT) has been shown to increase renal allogralt survival [8, 9] , probably due to immune suppression [10, 11] . A suppressive effect of this kind was also obtained with the transfusion of leukocytes [12] but not with leukocyte free RBC, which caused a decrease in graft survival in a few patients [13] . This may suggest an immune stimulatory effect of RBC in vivo.
Indeed, a decrease in various T and B cell functions has been described in children [14] and mice [15] with iron deficiency anemia.
Uremia is an immune suppressed state [16] . Various factors cause this immune suppression [17, 18] . Despite efficient dialysis treatment, several suppressed immune functions are not corrected. Since uremia is almost invariably associated with anemia, we postulated that the immune deficiency of uremia might be associated in part with the anemia.
The aim of this study was twofold. To evaluate a possible contributory effect of anemia to immune deficiency of uremia, and to investigate a potentiating effect of RBC on PBMC in vivo as expressed by in vitro secretion of cytokines.
Patients with end-stage renal disease (ESRD) and anemia, and healthy volunteers were studied. Cytokine secretion by PBMC was used as a measure of immune competence and function. Several protocols investigated the effect of changes in hemoglobin on cytokine secretion. In the first protocol the correlation between hemoglobin levels and interleukin-2 (IL-2) secretion was investigated in normal subjects and in a cohort of ESRD patients. In the second, the effect of an increase in hemoglobin induced by a single leukocyte-poor washed red blood cell (WRBC) transfusion on cytokine secretion by ESRD patients was studied. Studies were performed 4 hours, 4, 7, and 14 days after WRBC transfusion. In the third protocol, the effect of a gradual rise in hemoglobin induced by recombinant human erythropoietin (rHuEpo) administration on cytokine secretion was studied. The fourth protocol investigated the effects of decreasing and increasing hemoglobin levels on cytokine secretion in healthy volunteers. Phlebotomy and autologous WRBC transfusion were used to manipulate the hemoglobin level. The cytokines studied included IL-2, y-interferon (y-IFN), tumor necrosis factor (TNF) and colony stimulating factor (CSF).
The results of the study suggest that the RBC have an immunopotentiating effect demonstrated by their ability to increase cytokine secretion. Anemia of uremia is associated with a decreased ability to secrete cytokines which might be partially restored with rHuEpo treatment.
Methods

Subjects
The patient cohort consisted of ESRD patients who were undergoing regular dialysis treatment for at least six months. None had received blood transfusions for at least three months prior to the study. Normal volunteers served as controls.
Informed consent was obtained from all participants.
Protocol 1-Association between IL-2 and hemoglobin IL-2 secretion by PBMC was measured in 15 patients with ESRD whose age was 45 5 years. They received regular hemodialysis treatment four hours thrice weekly with a Cuprophan membrane dialyzer and acetate containing dialysate. The diseases which led to ESRD were: chronic glomerulonephritis (4 patients), interstitial nephropathy (2), refiux nephropathy (2), diabetic nephropathy (2), atherosclerotic renal artery occlusion (1), systemic lupus erythematosus (SLE) (1), and unknown etiology (2) . These patients were on dialysis for six months to 12 years. They did not suffer from a recent infection and were not treated with immunosuppressive drugs. They had not received blood transfusions for at least three months prior to the study and had not been treated with rHuEpo. Two of them received a kidney transplant which was rejected 10 and six years prior to the study. The patient with SLE has been on hemodialysis for 12 years; her disease was already inactive when dialysis was initiated. Twenty volunteers whose age was 42 1 years served as control. Hemoglobin, urea and creatinine were measured simultaneously.
Protocol 2-Effect of RBC transfusion on cytokine secretion
Six patients with ESRD received a transfusion of WRBCs. The RBCs were washed three times and infused to the patients through a nylon filter (Miramed, Mirandola, Italy) to obtain a 97 to 98% leukocyte free unit. The transfusion was given on a day between dialyses. Blood samples were obtained pre-transfusion and at 4 hours, 4, 7 and 14 days post-transfusion. Blood samples on days 4, 7 and 14 were obtained prior to hemodialysis. PBMC were isolated, and IL-2, y-IFN, TNF and CSF secretion were determined. Post-transfusion results were compared to pretransfusion results which served as controls.
Protocol 3-Effect of rHuEpo on cytokine secretion
(a) Five women with ESRD on regular hemodialysis treatment were studied. They received rHuEpo (Eprex, Cilag, Switzerland) at a dose of 50 U/kg body weight X 3/week. After a month, the dose was increased to about 75 U/kg x 3/week and this dose was sustained throughout the study. Cytokine secretion was determined before initiating rHuEpo treat-ment, and after two and four months of treatment. The determinations of IL-2 and y-IFN were performed with both bio-and immunoassays. One patient underwent a cadaver kidney transplantation just prior to the final cytokine secretion determination.
(b) The in vitro effect of rHuEpo on IL-2 secretion was examined. rHuEpo at a final concentration of 0.1, 0.5, 1, 10, 50 and 100 U/ml was added to the PBMC in culture. IL-2 secretion was measured as described.
Protocol 4-Effect of phlebotomy andautologous RBC transfusion on cytokine secretion
Eleven volunteers, nine women and two men, whose age was 42 5 years were studied. One unit of blood (approximately 450 ml) was phlebotomized into a double blood pack and stored at 4°C. Three weeks later, each subject was transfused with his own RBCs following leukocyte removal as described in Protocol 2.
Cytokine secretion was measured before phlebotomy and at one and three weeks postphlebotomy prior to autotransfusion.
One and two weeks post-transfusion samples were also obtained. The interval between phlebotomy and autotransfusion was chosen since preliminary studies have indicated restoration of the hemoglobin level three weeks postphlebotomy.
Reagents
Reagents used in this study were Concanavalin A (Con A; Miles Yeda, Rehovot, Israel); phytohemagglutinin (PHA-M; Difco Lab., St. Louis, Missouri, USA); lipopolysacharide (LPS from S. Abortus Equi; Difco Lab., Detroit, Michigan, USA); actinomycin D (Dactinomycin, Merck, New Jersey, USA); fetal calf serum (FCS; Maagar, Beit Haemek, Israel). Enriched RPMI-1640 (GIBCO) was supplemented with 10% FCS, 2 mM L-glutamine, 10 m nonessential amino acids, 3 m sodium pyruvate, 5 X iO-M 2-ME, 100 IU/ml penicillin, and 100 g/ml streptomycin.
Cell preparation PBMC were isolated following Ficol-Hypaque gradient centrifugation. The isolated PBMC were washed and suspended in enriched RPMI-1640 at a concentration of 106/ml.
Quantitation of IL-2
Bioassay. The ability of the supernatant fraction to support the growth of the IL-2 dependent CTLL clone was used to assay IL-2 production. CTLL cells (10 per well) were seeded in triplicates in culture medium, with or without dilutions of the supernatant fraction. After 48 hours, 3H-TdR uptake was determined in a liquid scintillation counter. One unit of IL-2 activity was defined as the reciprocal log2 dilution required to give 50% of the maximal proliferation of io IL-2 dependent murine CTLL cells after 48 hours of culture.
Immunoassay. Quantitative measurements of IL-2 in the supernatants were carried out with an enzyme-linked Elisa immunoassay kit (T-Cell Diagnostic Inc., Cambridge, Massachusetts, USA).
Assay for CSF activity CSF was quantitated by determining the number of colonies that developed from blood mononuclear (BM) cells cloned in the presence of the CSF-containing fraction to be tested. The soft agar technique described by Pluznik and Sachs [19] was used to clone BM cells. Briefly, supernatants containing CSF were incorporated in 2 ml of hard medium in a 35 mm Petri dish.
iO BM cells in 1 ml of soft agar medium (0.3%) were cloned above the hard agar layer. After seven days of incubation at 37°C in a humidified atmosphere of 8.5% CO2 in air, the number of colonies that had grown in the soft agar layer was scored. Immunoassay. Quantitative measurements of 'y.IFN in the supernatants were carried out with an enzyme-linked Elisa immunoassay-kit (T-Cell Diagnostic Inc., Cambridge, Massachusetts, USA).
Assay for tumor necrosis factor
Production of cytokines
Human PBMC 106/ml cells were suspended in enriched RPMI-1640 medium with 10% FCS and 200 j.tg/ml PHA-M. The cultures were incubated for 48 or 96 hours. Supernatants were collected and assayed for either IL-2, or CSF (after 48 hr of incubation) or for TNF and y-IFN (after 96 hr of incubation). Rat spleen cells, treated by hypotonic shock to lyze erythrocytes, were cultured at 5 x 106/ml for 48 hours (for IL-2 and CSF) or 1 x 106/ml for 24 hours (for IL-3) in enriched RPM!-1640 medium with 10% FCS and 2.5 sg/ml Con A. Supernatants were collected and tested for the specific cytokines.
Statistical analysis
Data are presented as mean SE. Comparisons between groups were made with the Student's t-test for paired or unpaired data as needed. Pearson's correlation coefficient was calculated for analysis of correlations between IL-2 secretion and hemoglobin level in protocol 1, and for correlations between results of bioassays and immunoassays of IL-2 and y-IFN in protocol 3. Correlations between secretion of various cytokines and hemoglobin levels at the different time points in protocols 3 and 4 were analyzed using multiple analysis of variants (MANOVA) with repeated measures.
Results
Association between IL-2 and hemoglobin
The secretion of IL-2 by PBMC from patients with ESRD was 7.7 1.6 U/mi significantly less than IL-2 secretion by the control group (31.2 2.6; P < 0.001). Similarly, hemoglobin levels of the patients with ESRD was much lower than that of the controls (7.8 0.5 vs. 13.0 1.3 g/dl; P <0.005). Figure 1A illustrates the correlation between IL-2 secretion and hemoglobin levels of the patients with ESRD. A direct correlation was found (r = 0.73, P < 0.01). The correlation between IL-2 secretion and hemoglobin levels of the controls is depicted in (r = 0.71, P < 0.01). No correlation was found between IL-2 and urea or creatinine.
Effect of RBC transfusion on cytokine secretion in patients with ESRD
The acute effect of WRBC on cytokine secretion by PBMC is illustrated in Figure 2 . As shown in Figure 2A , a single transfusion of RBC to patients with ESRD caused an immediate rise in IL-2 from 6.5 5.1 to 11.8 7.2 U/ml (P < 0.05). Four days later, the IL-2 level reached 14.4 7.7 U/mi (P < 0.025). One week after the transfusion, IL-2 levels were 13.6 7.6 U/mi (P < 0.025). Two weeks after the transfusion, the IL-2 level was 12. 2 8.4 U/mi, which was not different from baseline. Figure 2B illustrates changes in y-IFN. The basal level was 105 34 U/ml. After four hours it was 225 87 U/mi. Four days after the transfusion, y-IFN rose significantly to 265 97 U/mi (P < 0.05); at one week it was slightly higher at 336 88 U/mi (P <0.01), and at two weeks it was 300 80 U/ml (P < 0.01). Figure 2C illustrates the changes in TNF post-transfusion. The TNF level was 4 1.7 U/mi pre-transfusion and 12.8 5.3 U/ml four hours post-transfusion. After four days it was still significantly elevated (8 2.2; P < 0.05); after one week it was 16 5.7 (P < 0.05), and after two weeks 11.2 2.0 (P < 0.001). The changes in CSF are shown in Figure 2D . The pattern of change was similar to that seen with the other cytokines. The basal level of 39. 
Effect of rHuEpo on cytokine secretion in patients with ESRD
The effect of a gradual change in hemoglobin on cytokine secretion was evaluated in five women with ESRD who were treated with rHuEpo intravenously. Their hemoglobin level before the rHuEpo treatment was 6.1 0.4 g/dl. Two months later it was 9.1 0.4 g/dl (P < 0.005), and after four months of treatment it was 11.5 0.6 g/dl (P < 0.001). Changes in IL-2 secretion associated with rHuEpo treatment measured by the bioassay are shown in Figure 3 . The IL-2 level was 4.0 2.4 U/mi before rHuEpo treatment. After two months of treatment it was 8.8 4.4 U/mi and after four months it rose to 21.5 5.7 U/mI (P < 0.01). Immunoassay measurements of IL-2 secretion in this protocol were also performed. Before rHuEpo treatment IL-2 level was 163 97 pg/ml. After two months of treatment it was 325 145 pg/mI and after four months it rose significantly to 658 73 pg/mi (P < 0.02). The bioassay determinations showed a highly significant correlation with immunoassay determinations (r = 0.937, P < 0.0001). To evaluate the correlation between IL-2 secretion and the hemoglobin level at the three time points MANOVA with repeated measures was used; indeed, a positive correlation was found (P <0.015).
The response of y-IFN to rHuEpo treatment as determined by the bioassay is shown in Figure 4 . y-IFN concentration rose from a level of 216 70 to 1152 192 U/mI after two months (P < 0.005). This level was maintained at four months 1152 215 U/mI (P < 0.005). Measurement of )4FN by immunoassay revealed a similar pattern to that found in the bioassay. Before rHuEpo treatment 'y-IFN concentration was 323 85 pg/0. 1 ml, after two months of treatment it rose to 1827 334 pgIO. 1 ml (P < 0.005), and four months after the beginning of rHuEpo treatment the y-IFN level was 1980 427 pg/0. 1 ml (P < 0.005). The bioassay showed a positive correlation with the immunoassay (r = 0.997, P < 0.0001). A possible correlation between y-INF secretion and the hemoglobin level at the different time points was tested using MANOVA with repeated measures. A positive correlation was found (P < 0.018).
The effect of rHuEpo treatment on TNF secretion is shown in Figure 5 . TNF concentration rose from 9.6 2.7 U/mi before treatment to 24.0 5.1 U/mI two months after initiation of treatment (P < 0.01). After four months of treatment the level was 44.0 12.0 U/mI (P < 0.025). Again a positive correlation was found between TNF and hemoglobin levels (P < 0.013). The response of CSF followed a similar pattern. Following two months of treatment its concentration rose from 47.4 6.2 Co/BMC to 59.2 6.5 Co/BMC (P < 0.01). After four months of treatment its concentration reached 70.3 4.5 Co/BMC (P < 0.01) (Fig. 6) . A positive correlation between CSF secretion and hemoglobin level was also found (P < 0.002).
During treatment with rHuEpo, serum ferritin level decreased in all patients. Before initiation of treatment with rHuEpo, serum ferritin was 542.6 179.2 g/liter, after four months of treatment it decreased to 412.8 158.7 pg/liter (P < 0.05).
In vitro effect of rHuEpo on IL-2 secretion by PBMC from healthy subjects, Basal IL-2 secretion by PBMC was 24.5 3.1 U/ml, with the addition of 0.1 ilml rHuEpo, IL-2 secretion was 23.8 2.5 U/ml, with 1 U/mi rHuEpo it was 24.5 U/mi, and with 5 U/ml rHuEpo it was 26. 
Effect of phlebotomy and autologous RBC transfusion on
cytokine secretion in healthy subjects The hemoglobin level prior to phlebotomy was 13.2 0.4 g/dl, one week post-phlebotomy it decreased significantly to 11.9 0.4 g/dl (P < 0.001), and three weeks postphlebotomy it was 12.4 0.4 g/dl slightly less than the basal level (P < 0.001). One week following the autologous WRBC transfusion, hemoglobin levels rose to 13.5 0.5 g/dl and two weeks after transfusion the hemoglobin level was 13.3 0.4 g/dl. Both values were not different from the prephlebotomy hemoglobin level. Figure 7A illustrates the response of IL-2 secretion. The prephiebotomy level of 32.2 1.6 U/mi was decreased at one week postphlebotomy to 25.2 1.5 U/ml (P < 0.001), and at three weeks postphlebotomy the IL-2 secretion was 31.4 1.6 U/mi similar to the prephlebotomy level. One week after autologous WRBC transfusion IL-2 secretion rose to 38.3 1.9, which was significantly higher than before phlebotomy (P <0.001), and two weeks post-autologous WRBC transfusion it was still elevated to 39.4 1.5 U/ml (P < 0.001 vs. prephiebotomy). IL-2 secretion correlated directly with the hemoglobin level at the different time points (P <0.0001).
The response of y-IFN is depicted in Figure 8 . Prephlebotomy y-IFN secretion was 210.0 60.2 U/mi; one week postphlebotomy it decreased substantially to 73.1 23 0.001 vs. prephiebotomy). A direct correlation was found between y-IFN secretion and hemoglobin levels (P < 0.0001). Figure 9 illustrates the TNF response. Prephiebotomy TNF secretion was 139. 6 28.4 U/mI. One week postphlebotomy it decreased to 58.2 11.3 U/mi (P < 0.002) and by three weeks postphlebotomy the secretion rate was restored (139.6 28.4 U/mi). RBC transfusion raised secretion of TNF to 343.3 52 U/mi (P < 0.001). This high secretion rate was maintained at two weeks post-transfusion 331.6 46.3 U/mi (P < 0.001). A direct correlation was found between TNF secretion and the hemoglobin level (P < 0.0001). Figure 10 shows the response of CSF. Prephiebotomy secretion was 70.3 4.1 Co/BMC. One week postphlebotomy it decreased to 49.9 2.7 Co/BMC (P < 0.001) and three weeks postphelbotomy the secretion rate normalized at 70.3 5.3 Co/BMC. Following autologous WRBC transfusion, secretion increased to 108. Phlebotomy in healthy subjects was associated with reduction in IL-2, y-IFN, TNF and CSF secretion which was restored by three weeks in parallel with the spontaneous rise in the hemoglobin level. Transfusion of autologous blood led to an additional rise in the secretion of these cytokines. The changes in cytokine secretion again correlated positively with those of the hemoglobin level. Two separate, although linked effects, on cytokine secretion by PBMC in vitro emerged from these studies. One effect is associated with the level of anemia and is expressed by direct correlation between the secretion of cytokines in vitro and the blood hemoglobin level. The other effect is related to the immunomodulatory impact of acute RBC transfusion which is observed early after transfusion and which lasts unrelated to the hemoglobin level.
In vitro studies have demonstrated stimulation of T and B cells by RBC [1-.7] . The present study demonstrates an in vivo stimulation of PBMC by RBC which is manifested by enhanced secretion of cytokines. This effect was obtained with both homologous and autologous RBC, suggesting that it is independent of the major histocompatibility complex. Similar results were found in in vitro studies which showed enhancement of PHA stimulation [1] and natural killer mediated cytotoxicity [2] by autologous, homologous or heterologous RBC. 
Activation of mononuclear cells by RBC could occur indi-
rectly as suggested by Tarnvik [1] . He postulated that the increased response of mononuclear cells to PHA is achieved by binding the mitogen to the RBC and presenting it to the responding cell in a favorable manner. Another possibility is a direct activation of lymphocytes by RBC. The sheep RBC receptor (CD2) on human T lymphocytes is a surface glycoprotein present on all mature T cells [20] . Its natural ligand is a broadly distributed cell adhesion molecule designated as lymphocyte function associated antigen 3 (LFA-3) [21] . Recently, this antigen has been shown to be expressed on RBC [22, 23] . The interaction between CD2 and its ligand LFA-3 has been shown to deliver activating signals to human T lymphocytes [24] . The effect of RBC on lymphocytes has been shown to be abrogated by preincubation of lymphocytes with anti-CD2 antibodies or by pretreatment of RBC with anti-LFA-3 monoclonal antibodies [25, 261 . A recent study from our laboratory [7] has shown enhancement of the secretion of various cytokines by human PBMC and mouse spleen cells in the presence of autologous RBC. This enhanced secretion of cytokines was abrogated when human PBMC and mouse spleen cells were pretreated with human or mouse anti-CD2 antibodies, respectively. This suggests that RBC may enhance cytokine secretion via interaction between LFA-3 molecules on the RBC and the lymphocyte CD2 molecules.
Other factors which may influence cytokine secretion independently of RBC could include iron and rHuEpo. Iron deficiency may impair lymphocyte proliferation [27] , and indeed, iron deficiency anemia has been associated with immune deficiency [14, 15] . In the present study treatment with rHuEpo led to a rise in hemoglobin levels and cytokine secretion with a simultaneous decrease in the blood level of ferritin. It is therefore unlikely that iron affected cytokine secretion. The results in this study suggest that the effect of rHuEpo on cytokine secretion is indirect through the RBC. This is based on the direct correlation between hemoglobin levels and cytokine secretion following rHuEpo treatment. Furthermore, a direct correlation between the hemoglobin level and cytokine secretion was found when the hemoglobin level was changed with either transfusion or phlebotomy. These protocols have probably driven endogenous erythropoietin blood concentration in the opposite direction of the hemoglobin level and cytokine secretion. A direct effect of rHuEpo on IL-2 secretion by PBMC was examined in the in vitro protocol. There was no effect of rHuEpo in concentrations which ranged from physiological up to 100,000 mU/mi. Similar results were reported from other laboratories [28] . It is noteworthy that rHuEpo treatment with 200 U/kg body weight daily given to candidates for major cardiac surgery led to more than a three-fold increase in IL-2 secretion [29] . Contrary to its effect on T cells and monocytes, rHuEpo seems to activate B cells directly. Treatment with rHuEpo in patients with ESRD led to enhanced secretion of immunoglobulins by PBMC which was independent of RBC [28] . Moreover, the addition of rHuEpo Ui Vitro enhanced secretion of IgG and IgA by PBMC [28] and the secretion of IgE by PBMC isolated from atopic subjects [30] . It also enhanced 1gM secretion by a lymphoblastoid cell line [31] . The concentration of rHuEpo in the in vitro studies was pharmacological.
In this study we employed protocols whereby RBC mass was modulated in vivo, However, the effect of changes in the hemoglobin level by rHuEpo treatment, phlebotomy or that of RBC transfusion on PBMC was tested in vitro, that is, secretion of cytokines in culture. Due to the limitations of the method used, conclusions regarding clinical relevance need further substantiation by clinical studies. It is noteworthy that treatment with rHuEpo which raised the hemoglobin level in patients with ESRD led to a decrease or no change in other immune functions. Thus, the response to PHA stimulation and mixed lymphocyte reaction (MLR) were decreased [32] or unchanged [33] . However, in cardiac surgery patients treatment with rHuEpo increased the response to PHA stimulation [29] . Based on the reasults of this study augmentation of the response to PHA stimulation and MLR would have been expected. However, data regarding PHA stimulation and MLR are inconsistent. In addition, various immune responses may react differently to similar stimuli. In clinical practice the treatment with rHuEpo led to a reduction in the percent of panel reactive antibodies (PRA%) in sensitized patients awaiting kidney transplantation [32, 33] . This reduction in PRA% is most probably the result of the decrease in the number of blood transfusions [34] .
A preliminary report suggested that pre-transplantation rHuEpo treatment and a high pre-transpiantation hematocrit were associated with a prolonged post-transplantation dialysis and prolonged post-transplantation anuria [35] .
In summary, taking into consideration the limitations of the methodology used, the RBC seem to have a potentiating effect on cytokine secretion. Anemia of patients with ESRD may be associated with decreased cytokine secretion and thereby may contribute to their immune deficiency. Treatment with rHuEpo or RBC transfusion might restore in part the patients' ability to secrete cytokines.
